February 25, 2009 — In premenopausal women with early breast cancer, adjuvant therapy with the luteinizing hormone-releasing hormone agonist goserelin (Zoladex, AstraZeneca) decreases the long-term ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. A drug that reduces the amount of estrogen in the body can help prevent ...

Final results of a clinical trial show continued evidence that women who get injections of the hormone drug goserelin along with standard breast cancer chemotherapy are more likely to become pregnant ...

Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra ...

In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were allocated to ...

Cincinnati--Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...